Mice over-expressing the 5-HT transporter gene develop pulmonary hypertension Source: Annual Congress 2004 - Pathophysiology of pulmonary hypertension Year: 2004
Overexpression of serotonin receptor 1B (5HT-1B) responsible for overflow induced experimental pulmonary arterial hypertension development Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation Year: 2003
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Polymorphism of the serotonin transporter and 2a receptor gene in COPD with and without pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008
Blockage of serotonin receptors and transporter reduces bleomycin lung fibrosis in mice Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 271s Year: 2003
Pulmonary arterial hypertension phenotype in VIP knockout mice Source: Eur Respir J 2006; 28: Suppl. 50, 546s Year: 2006
Hyperplasia of pulmonary artery smooth muscle cells in primary and secondary pulmonary hypertension is causally related to serotonin transporter overexpression Source: Eur Respir J 2002; 20: Suppl. 38, 5s Year: 2002
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation Source: Eur Respir J 2003; 22: 560-562 Year: 2003
α1 -adrenoceptor antagonism does not modify the pulmonary vasoconstrictor effect of dexfenfluramine in the rat Source: Eur Respir J 2001; 18: Suppl. 33, 491s Year: 2001
Tryptophan hydroxylase-1 inhibitors reduce serotonin levels and mast cell numbers in monocrotaline-treated rat lungs Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015
Reduction in serotonin signaling via TPH1 inhibition attenuates the progression of PAH in mice with genetic ablation of endothelial BMPR-II Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012
Dual endothelin-1 receptor antagonism prevents chronic intermittent hypoxia-induced cardiovascular alterations in rats Source: Annual Congress 2008 - Innovative treatments in sleep disordered breathing Year: 2008
Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Genistein rescues pulmonary hypertension and attenuates abnormal vasoconstriction in rats lungs Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive lung disease Source: Eur Respir J 2003; 22: Suppl. 45, 20s Year: 2003
BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives Source: Eur Respir J 2002; 20: 518-523 Year: 2002
Echocardiographyc and histomorphometric assessment of the effects of pharmacological antagonism of endothelin receptors in the Sugen 5416/hypoxia rat model of pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018
Effects of the NO donor molsidomine on prostacyclin synthase gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001
Effects of iptkalim hydrochloride on endothelin-1-induced pulmonary hypertension in rats Source: Eur Respir J 2005; 26: Suppl. 49, 291s Year: 2005